MX389073B - Método para producir una proteína de fusión de anticuerpo. - Google Patents
Método para producir una proteína de fusión de anticuerpo.Info
- Publication number
- MX389073B MX389073B MX2019002252A MX2019002252A MX389073B MX 389073 B MX389073 B MX 389073B MX 2019002252 A MX2019002252 A MX 2019002252A MX 2019002252 A MX2019002252 A MX 2019002252A MX 389073 B MX389073 B MX 389073B
- Authority
- MX
- Mexico
- Prior art keywords
- fusion protein
- producing
- column chromatography
- antibody
- fusing
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 7
- 238000004519 manufacturing process Methods 0.000 title abstract 4
- 102000037865 fusion proteins Human genes 0.000 abstract 6
- 238000004440 column chromatography Methods 0.000 abstract 3
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 230000005526 G1 to G0 transition Effects 0.000 abstract 2
- 239000012228 culture supernatant Substances 0.000 abstract 2
- 230000002132 lysosomal effect Effects 0.000 abstract 2
- 210000004962 mammalian cell Anatomy 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 2
- 238000012258 culturing Methods 0.000 abstract 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- 239000012679 serum free medium Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016164901 | 2016-08-25 | ||
| PCT/JP2017/030470 WO2018038243A1 (ja) | 2016-08-25 | 2017-08-25 | 抗体融合蛋白質の製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019002252A MX2019002252A (es) | 2019-07-04 |
| MX389073B true MX389073B (es) | 2025-03-20 |
Family
ID=61246169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002252A MX389073B (es) | 2016-08-25 | 2017-08-25 | Método para producir una proteína de fusión de anticuerpo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11512135B2 (enExample) |
| EP (1) | EP3505538B1 (enExample) |
| JP (2) | JP6993814B2 (enExample) |
| KR (1) | KR102318480B1 (enExample) |
| CN (1) | CN109641971B (enExample) |
| AU (1) | AU2017316955B2 (enExample) |
| BR (1) | BR112019003622A2 (enExample) |
| CA (1) | CA3034589A1 (enExample) |
| MX (1) | MX389073B (enExample) |
| SG (1) | SG11201901495YA (enExample) |
| WO (1) | WO2018038243A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6914193B2 (ja) | 2015-06-24 | 2021-08-04 | Ｊｃｒファーマ株式会社 | Ｂｄｎｆを含む融合蛋白質 |
| TWI769982B (zh) | 2015-06-24 | 2022-07-11 | 日商Ｊｃｒ製藥股份有限公司 | 通過血腦障壁之抗人類運鐵蛋白受體抗體 |
| NZ752703A (en) | 2016-12-26 | 2022-09-30 | Japan Chem Res | Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier |
| EP3561058B1 (en) | 2016-12-26 | 2025-07-23 | JCR Pharmaceuticals Co., Ltd. | Fusion protein including bdnf |
| WO2019049967A1 (ja) | 2017-09-07 | 2019-03-14 | Ｊｃｒファーマ株式会社 | 水性医薬組成物 |
| CA3076369A1 (en) | 2017-10-02 | 2019-04-11 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| US20210038739A1 (en) * | 2018-02-05 | 2021-02-11 | Jcr Pharmaceuticals Co., Ltd. | Method for Delivering Drug to Muscle |
| EP3560945A1 (en) * | 2018-04-27 | 2019-10-30 | F. Hoffmann-La Roche AG | Methods for purification of polypeptides using polysorbates |
| JP6951051B2 (ja) * | 2018-05-24 | 2021-10-20 | ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 | 吸着剤の生産方法 |
| KR102692543B1 (ko) * | 2018-10-26 | 2024-08-07 | 재단법인 목암생명과학연구소 | Ids를 포함하는 융합 단백질 및 이의 용도 |
| MA71661A (fr) | 2020-10-14 | 2025-05-30 | Denali Therapeutics Inc. | Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées |
| WO2022135457A1 (zh) * | 2020-12-23 | 2022-06-30 | 广东菲鹏制药股份有限公司 | 一种抗pd-l1抗体及其应用 |
| CN116997364A (zh) * | 2021-02-11 | 2023-11-03 | 戴纳立制药公司 | 抗转铁蛋白受体融合蛋白及其使用方法 |
| JP2022138142A (ja) | 2021-03-09 | 2022-09-22 | Ｊｃｒファーマ株式会社 | 抗体－リソソーム酵素融合蛋白質の製造方法 |
| WO2023127879A1 (ja) * | 2021-12-28 | 2023-07-06 | Ｊｃｒファーマ株式会社 | 安全な遺伝子治療のための抗トランスフェリン受容体抗体と生理活性を有する蛋白質との融合蛋白質 |
| JPWO2024010067A1 (enExample) * | 2022-07-08 | 2024-01-11 | ||
| WO2025137213A1 (en) | 2023-12-20 | 2025-06-26 | Denali Therapeutics Inc. | Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006069036A2 (en) * | 2004-12-21 | 2006-06-29 | Centocor, Inc. | Anti-il-12 antibodies, epitopes, compositions, methods and uses |
| EP1670931A2 (en) * | 2003-09-05 | 2006-06-21 | GTC Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| JP5065391B2 (ja) | 2006-12-06 | 2012-10-31 | 日本ケミカルリサーチ株式会社 | ヒトエリスロポエチンの製造方法 |
| WO2008072075A2 (en) * | 2006-12-12 | 2008-06-19 | Biorexis Pharmaceutical Corporation | Transferrin fusion protein libraries |
| JP2009273427A (ja) | 2008-05-16 | 2009-11-26 | Jcr Pharmaceuticals Co Ltd | 組換え体ヒトｆｓｈの製造方法 |
| ES2699434T3 (es) | 2008-10-31 | 2019-02-11 | Wyeth Llc | Purificación de proteínas ácidas utilizando cromatografía de hidroxiapatita cerámica |
| EP2485761B1 (en) * | 2009-10-09 | 2019-02-27 | Armagen, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
| JP6018572B2 (ja) * | 2011-01-25 | 2016-11-02 | Ｊｃｒファーマ株式会社 | 組換えヒトイズロン酸−２−スルファターゼの製造方法 |
| WO2012101671A1 (en) | 2011-01-25 | 2012-08-02 | Jcr Pharmaceuticals Co., Ltd. | Method for production of human recombinant iduronate 2-sulfatase |
| BR112014013250A2 (pt) * | 2011-12-01 | 2019-09-24 | Angiochem Inc | compostos com enzima alvo e usos dos mesmos |
| KR101380740B1 (ko) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
| WO2014016873A1 (en) | 2012-07-26 | 2014-01-30 | Jcr Pharmaceuticals Co., Ltd. | Method for production of recombinant human alpha-galactosidase a |
| WO2015098989A1 (ja) | 2013-12-25 | 2015-07-02 | Ｊｃｒファーマ株式会社 | 血液脳関門を通過する新規抗トランスフェリン受容体抗体 |
| JP6071018B2 (ja) | 2014-10-31 | 2017-02-01 | Ｊｃｒファーマ株式会社 | 組換えヒトＤＮａｓｅＩの製造方法 |
| WO2016116966A1 (en) | 2015-01-22 | 2016-07-28 | Jcr Pharmaceuticals Co., Ltd. | Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins |
-
2017
- 2017-08-25 AU AU2017316955A patent/AU2017316955B2/en active Active
- 2017-08-25 WO PCT/JP2017/030470 patent/WO2018038243A1/ja not_active Ceased
- 2017-08-25 CA CA3034589A patent/CA3034589A1/en active Pending
- 2017-08-25 BR BR112019003622-9A patent/BR112019003622A2/pt unknown
- 2017-08-25 JP JP2017161826A patent/JP6993814B2/ja active Active
- 2017-08-25 CN CN201780051299.5A patent/CN109641971B/zh active Active
- 2017-08-25 MX MX2019002252A patent/MX389073B/es unknown
- 2017-08-25 KR KR1020197007992A patent/KR102318480B1/ko active Active
- 2017-08-25 EP EP17843719.0A patent/EP3505538B1/en active Active
- 2017-08-25 SG SG11201901495YA patent/SG11201901495YA/en unknown
- 2017-08-25 US US16/327,982 patent/US11512135B2/en active Active
-
2021
- 2021-12-10 JP JP2021200504A patent/JP7232889B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7232889B2 (ja) | 2023-03-03 |
| MX2019002252A (es) | 2019-07-04 |
| SG11201901495YA (en) | 2019-03-28 |
| US20190225700A1 (en) | 2019-07-25 |
| CA3034589A1 (en) | 2018-03-01 |
| BR112019003622A2 (pt) | 2019-05-21 |
| JP2018033454A (ja) | 2018-03-08 |
| EP3505538A1 (en) | 2019-07-03 |
| CN109641971A (zh) | 2019-04-16 |
| KR20190040040A (ko) | 2019-04-16 |
| JP6993814B2 (ja) | 2022-01-14 |
| AU2017316955B2 (en) | 2022-03-03 |
| EP3505538A4 (en) | 2020-03-18 |
| EP3505538B1 (en) | 2024-05-01 |
| KR102318480B1 (ko) | 2021-10-28 |
| US11512135B2 (en) | 2022-11-29 |
| WO2018038243A1 (ja) | 2018-03-01 |
| JP2022028959A (ja) | 2022-02-16 |
| CN109641971B (zh) | 2023-04-04 |
| AU2017316955A1 (en) | 2019-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX389073B (es) | Método para producir una proteína de fusión de anticuerpo. | |
| EA201991976A1 (ru) | Метаболически оптимизированная клеточная культура | |
| EP4148121A3 (en) | Cell-controlled perfusion in continuous culture | |
| EP3539982A3 (en) | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor | |
| EA201492185A1 (ru) | Способ получения рекомбинантной идуронат-2-сульфатазы | |
| MX372711B (es) | Metodos para la purificacion de arilsulfatasa a. | |
| WO2019014310A8 (en) | Biological methods for preparing terpenes | |
| MY181513A (en) | Cell culture compositions and methods for polypeptide production | |
| EP3597664A3 (en) | Temperature shift for high yield expression of polypeptides in yeast and other transformed cells | |
| PH12020550927A1 (en) | Therapeutic enzyme fusion protein having novel structure and use thereof | |
| EA201492177A1 (ru) | Очистка идуронат-2-сульфатазы | |
| PH12016502406A1 (en) | Cell culture process for producing a protein | |
| BR112016012229A2 (pt) | métodos de produção de polipeptídeos | |
| PH12020550732A1 (en) | Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins | |
| MX2022001420A (es) | Proteinas inmovilizadas y uso de las mismas. | |
| MX2018004580A (es) | Metodo para producir proteina de fusion con dominio fc de igg. | |
| PH12020500054A1 (en) | Novel therapeutic enzyme fusion protein and use thereof | |
| BR112023018268A2 (pt) | Método para produzir uma proteína de fusão | |
| PL2059525T3 (pl) | Cząstki z rozszczepionym rdzeniem dla prezentacji obcych molekuł, w szczególności do zastosowań jako szczepionka oraz sposób ich wytwarzania | |
| AR097805A1 (es) | Células de cambio de temperatura para la expresión de alto rendimiento de polipéptidos en levadura y otros transformados | |
| SG11201806843UA (en) | Method for producing activated hepatocyte growth factor (hgf) | |
| EA200900984A1 (ru) | Улучшение клеточного роста | |
| WO2019183358A3 (en) | Whole cell processes to produce nitroaromatics | |
| WO2010082097A3 (pt) | Proteínas de fusão, processo para a sua preparação e sua utilização em sistemas de expressão de proteínas recombinantes | |
| EP3650043A3 (en) | Compositions and treatments for haemophilus influenzae |